FORGHIERI, Fabio
 Distribuzione geografica
Continente #
NA - Nord America 11.019
EU - Europa 4.808
AS - Asia 4.414
SA - Sud America 553
AF - Africa 95
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 10
Totale 20.916
Nazione #
US - Stati Uniti d'America 10.842
GB - Regno Unito 1.400
SG - Singapore 1.277
CN - Cina 1.082
IT - Italia 923
SE - Svezia 596
HK - Hong Kong 579
VN - Vietnam 520
DE - Germania 415
FI - Finlandia 407
BR - Brasile 405
RU - Federazione Russa 236
BD - Bangladesh 221
FR - Francia 220
UA - Ucraina 186
IN - India 140
TR - Turchia 138
KR - Corea 96
CA - Canada 81
BG - Bulgaria 71
ID - Indonesia 66
JP - Giappone 64
NL - Olanda 55
AR - Argentina 49
BE - Belgio 44
MX - Messico 42
IQ - Iraq 40
CZ - Repubblica Ceca 38
ES - Italia 35
IE - Irlanda 27
PL - Polonia 25
LT - Lituania 23
ZA - Sudafrica 23
EC - Ecuador 22
AE - Emirati Arabi Uniti 21
CO - Colombia 19
IR - Iran 19
AT - Austria 16
CL - Cile 16
MA - Marocco 16
PK - Pakistan 16
PY - Paraguay 15
UZ - Uzbekistan 15
AZ - Azerbaigian 14
CH - Svizzera 14
BZ - Belize 13
EG - Egitto 13
JO - Giordania 13
EU - Europa 12
VE - Venezuela 12
DK - Danimarca 11
KE - Kenya 11
PH - Filippine 11
SA - Arabia Saudita 10
SK - Slovacchia (Repubblica Slovacca) 10
AU - Australia 9
MY - Malesia 9
CR - Costa Rica 8
IL - Israele 8
JM - Giamaica 8
RO - Romania 8
TN - Tunisia 8
PT - Portogallo 7
TW - Taiwan 7
DZ - Algeria 6
UY - Uruguay 6
AL - Albania 5
CY - Cipro 5
ET - Etiopia 5
GR - Grecia 5
GT - Guatemala 5
LB - Libano 5
NO - Norvegia 5
NP - Nepal 5
PE - Perù 5
PS - Palestinian Territory 5
RS - Serbia 5
OM - Oman 4
PA - Panama 4
QA - Qatar 4
BH - Bahrain 3
BO - Bolivia 3
DO - Repubblica Dominicana 3
EE - Estonia 3
KG - Kirghizistan 3
MD - Moldavia 3
MK - Macedonia 3
NI - Nicaragua 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BY - Bielorussia 2
HN - Honduras 2
HU - Ungheria 2
KZ - Kazakistan 2
LV - Lettonia 2
SI - Slovenia 2
SN - Senegal 2
Totale 20.886
Città #
Ashburn 1.212
Fairfield 1.188
Southend 978
Santa Clara 866
Singapore 821
Woodbridge 746
Chandler 592
Hong Kong 568
Houston 563
Ann Arbor 455
Seattle 454
San Jose 448
Cambridge 357
Wilmington 338
Nyköping 331
Jacksonville 328
Dearborn 317
Helsinki 314
Hefei 251
Beijing 215
Modena 213
New York 211
London 193
Ho Chi Minh City 167
Los Angeles 152
Council Bluffs 135
Hanoi 116
Munich 98
The Dalles 95
Chicago 94
Milan 93
Seoul 81
San Diego 80
Fremont 73
Sofia 70
Bremen 67
Princeton 66
Lauterbourg 65
Izmir 64
Eugene 63
Buffalo 59
Moscow 56
Bologna 54
Dallas 54
Shanghai 53
Jakarta 43
Orem 40
São Paulo 38
Redwood City 34
Frankfurt am Main 33
Brussels 32
Rome 32
Columbus 31
Tokyo 31
Boardman 30
Atlanta 29
Da Nang 28
Salt Lake City 28
Turku 28
Brooklyn 27
Chennai 27
Montreal 26
Toronto 26
Dublin 25
Des Moines 24
Denver 18
Guangzhou 18
Las Vegas 17
Paris 17
Stockholm 17
Dong Ket 16
Phoenix 16
Warsaw 16
Baghdad 15
Haiphong 15
Miami 15
Miano 15
Mexico City 14
Mumbai 14
San Francisco 14
Tashkent 14
Washington 14
Albuquerque 13
Belize City 13
Boston 13
Kunming 13
Rio de Janeiro 13
Brno 12
Deventer 12
Johannesburg 12
Naples 12
Quito 12
Tampa 12
Hải Dương 11
Nairobi 11
Wuhan 11
Amsterdam 10
Leawood 10
Manchester 10
Memphis 10
Totale 14.901
Nome #
Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis 441
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 429
Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study 422
B cells and herpesviruses: a model of lymphoproliferation 408
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors 399
Helicobacter pylori infection andchronic immune thrombocytopenic purpura: long-term results of bacteriumeradication and association with bacterium virulence profiles 399
An unusual case of B-ALL occurring in a patient with acute promyelocytic leukemia in remission after two hematopoietic SCTs: whose are the leukemic cells? 382
Detection of Pneumocystis jirovecii and Aspergillus spp. DNa in bronchoalveolar lavage fluids by commercial real-time PCr assays: comparison with conventional diagnostic tests 373
NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms 371
Mucorales-specific T cells in patients with hematologic malignancies 363
Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study 358
Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term Imatinib mesylate treatment. 358
Acute appendicitis in adult neutropenic patients with hematologic malignancies 356
A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course. 354
Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia 347
Detection of Fusarium-specific T cells in hematologic patients with invasive fusariosis 345
Antineoplastic effects of liposomal siRNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma 340
An unusual case of splenomegaly and increased lactate dehydrogenase heralding acute myeloid leukemia with eosinophilia and RUNX1-MECOM fusion transcripts 338
Diagnosis of invasive aspergillosis by tracking Aspergillus-specific T cells in hematologic patients with pulmonary infiltrates 324
Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients. 324
Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. 322
Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma 321
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature 321
Human herpesvirus 6 latency characterized by high viral load: Chromosomal integration in many, but not all, cells 320
Atraumatic splenic rupture in patients with myelodysplastic syndromes: Report of a case occurred during treatment with 5-azacitidine and review of the literature. 319
The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi 311
Organising pneumonia mimicking invasive fungal disease in patients with leukaemia. 308
Chronic/relapsing lymphadenopathy associated with HHV-6B infection: a new benign clinico-pathologic entity occurring in immunocompetent individuals 304
Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirus-6B reactivation 300
BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy. 298
Human Herpesvirus 8 (HHV8) Infection and Related Diseases in Italian Transplant Cohorts. 292
Investigating the association between physicians self-efficacy regarding communication skills and risk of “burnout” 291
Epstein-Barr virusassociated pneumonia in an adult patient with severe aplastic anaemia: resolutionafter the transient withdrawal of cyclosporine. 286
Circulating functional T cells specific to human herpes virus 6 (HHV6) antigens in individuals with chromosomally integrated HHV6 286
Inflammatory myofibroblastic tumor of the bone marrow. 285
Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis 282
Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study 282
The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes 281
May the indirect effects of CIHHV-6 in transplant patients be exerted through the reactivation of the viral replicative machinery? 281
HHV-6 and atypical lymphoproliferative disorders: are only qualitative molecular examinations sufficient to support a pathogenetic role? 280
Pain and emotional distress in leukemia patients at diagnosis. 278
Common vascular endothelial growth factor variants and risk for posttransplant Kaposi sarcoma. 274
"Metodo per la diagnosi e/o il monitoraggio della mucormicosi" - "Method for the diagnosis of and/or monitoring mucormycosis" 271
Identification and characterization of Aspergillus-specific immune responses to diagnose invasive aspergillosis in high risk patients: a multicenter study 271
Veicolazione liposomiale del cidofovir nel trattamento del PEL (Primary Effusion Lynphoma) 269
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia 266
Indirect Antitumor Effects of Mammalian Target of Rapamycin Inhibitors Against Kaposi Sarcoma in Transplant Patients 265
Mucorles-specific T cells emerge in the course of invasive mucormucosis and may be used as a surrogate diagnostic marker in high-risk patients 263
Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL 262
BK virus infection and neurologic dysfunctions in a patient with lymphoma treated with chemotherapy and rituximab 261
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study 260
Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study 256
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers 255
How I treat HHV8/KSHV-related diseases in posttransplant patients. 254
Splenic hyalohyphomycosis, molecularly and immunologically consistent with invasive aspergillosis, in a patient with acute lymphoblastic leukemia. 248
Tumor-targeted immunoliposomal nanosystems to deliver either Cidofovir or Antineoplastic SiRNA against Primary Effusion Lymphoma (PEL) 243
Splenomegaly in hematological malignancies and portal hypertension 241
Acute promyelocytic leukemia in very elderly patients: still aclinical challenge. 235
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives 226
Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation 226
Early palliative/supportive care in acute myeloid leukaemia allows low aggression end-of-life interventions: Observational outpatient study 225
Philadelphia chromosome-positive acute lymphoblastic leukemia 225
Pain and emozional distress in hematological patients throughout all phases of disease: results from a multidisciplinary research team in Modena University Hospital 218
Ibrutinib Is a Newly Recognized Host Factor for the Definition of Probable Invasive Pulmonary Mold Disease, Based on Off-target Effects, Unrelated to Its B-cell Immunosuppressant Activity 205
Severe pneumonia caused by Legionella pneumophila serogroup 11, Italy. 200
May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML? 200
Persistent hiccups as an adverse event to FLAG-IDA regimenfor leukemia. 199
β-HHVs and HHV-8 in Lymphoproliferative Disorders. 186
Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells 169
Edmonton symptom assessment system Global Distress Score and overall survival in acute leukaemia 165
Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience 152
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia 150
Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients 140
The dynamic functions of IRF4 in B cell malignancies 105
Optical genome mapping reveals multiple apoptotic and cell-cycle pathway aberrations in B-cell prolymphocytic leukemia: a report of three cases 25
Quality of life and symptoms in acute myeloid leukaemia with early palliative care: real-world observational study 18
OPTICAL GENOME MAPPING IDENTIFIES MULTIPLE STRUCTURAL VARIATION AND CATASTROPHIC REARRANGEMENTS IN B-CELL PROLYMPHOCYTIC LEUKEMIA 12
CLINICAL OUTCOMES OF YOUNGER ADULT PATIENTS WITH PHILADELPHIANEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA, TREATED IN THE REAL-LIFE WITH A PEDIATRIC-LIKE REGIMEN BASED ON GIMEMA LAL1308 PROTOCOL: AN OBSERVATIONAL RETROSPECTIVE CAMPUS ALL STUDY 12
Hemopoietic stem cell transplantation for infectious mononucleosis-related aplastic anemia 9
Totale 21.140
Categoria #
all - tutte 76.615
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.615


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021139 0 0 0 0 0 0 0 0 0 0 0 139
2021/20221.553 69 208 160 96 32 71 85 83 140 145 296 168
2022/20231.765 231 219 109 173 273 203 58 169 163 23 72 72
2023/20241.191 33 48 92 88 215 139 137 210 23 22 77 107
2024/20253.149 129 44 72 214 567 464 237 175 397 96 284 470
2025/20266.289 480 241 414 572 884 466 888 331 667 541 492 313
Totale 21.140